16 results about "Ebastine" patented technology

The invention discloses an ebastine oral solution preparation method, which comprises: 1, weighing 5-20 parts by mass of ebastine, 50-100 parts by mass of a thickening agent, 10-18 parts by mass of a bacteriostatic agent, 1800-2000 parts by mass of a thickening agent, 0.1-0.2 part by mass of a defoaming agent, 600-700 parts by mass of a sweetening agent, adjusting the pH value to 3.5-4.5 by using a pH value adjusting agent, and carrying out a proper amount of water; 2, adjusting the temperature to 35 DEG C, adding ebastine into the thickening agent, and stirring to completely disperse the ebastine; 3, adding part of purified water, an acidity regulator and a thickening agent, and stirring until the materials are completely dissolved; 4, adding the sweetening agent, the bacteriostatic agent and the defoaming agent, and stirring until the materials are completely dissolved; 5, cooling after complete dissolution, and adjusting the pH value to 4 by using an alkaline regulator; step 6, fixing the volume; by optimizing the preparation process, efficient dissolution of the ebastine oral solution is realized, the problems of clinical application pain points of tablets and low solubility of raw material medicines of the oral solution are solved, and a safer and more convenient treatment choice is provided for special crowds.

The invention belongs to the field of biological medicine, and particularly relates to a fusobacterium nucleatum FtsZ protease inhibitor and application thereof. On the basis of the idea of new use of old drugs, drugs approved by FDA are subjected to structure-based virtual screening and molecular dynamics simulation, and sorafenib, ponatinib, ceritinib and ibastine can be stably combined to active sites of fusobacterium nucleatum FtsZ protease; in-vitro experiments also show that sorafenib, ponatinib, ceritinib and ibastine are inhibitors with the fusobacterium nucleatum FtsZ protease, so that new antibacterial applications of sorafenib, ponatinib, ceritinib and ibastine are explored. The invention not only provides a new angle for antibiotic discovery, but also provides an example for rapid development of a novel FtsZ protease inhibitor.

The present invention relates to an oral film containing ebastine and a preparation method thereof, belonging to the field of pharmaceutical technology. During the preparation of the mucilage, methylcellulose and polyacrylic resin are used as film-forming agents. When the mass ratio of the film-forming agent to purified water is controlled at 1:3 to 5, and the mass ratio of polyacrylic resin to methylcellulose in the film-forming agent is 0.5 to 2.5:1, the resulting mucilage is a viscous paste, the film has good flexibility and film-forming property, the film has no insoluble substances and good flexibility, has no bitter taste in terms of taste, has a cool and sweet taste, the active ingredient dissolves rapidly and fully, has good dissolution effect, stability, taste masking effect and compliance. Compared with the existing dosage forms on the market, it is more suitable for the elderly and children and has great clinical significance.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The invention discloses an ebastine tablet and a preparation method thereof. The ebastine tablet is prepared from the following raw material components in parts by weight: 7 to 10 parts of ebastine, 13 to 22 parts of microcrystalline cellulose, 66 to 90 parts of lactose, 3 to 6.5 parts of pregelatinized starch, 4 to 6.5 parts of croscarmellose sodium and 1.0 to 2.6 parts of magnesium stearate. A wet granulation process is adopted, granules prepared by the process are good in flowability and compressibility, qualified in quality and stable in property, and the medicine is a pH dependent medicine and cannot reach tank leakage conditions in media with the pH of 4.5, water and pH of 6.8. In combination with biological pharmacy and pharmacokinetic data of drugs, ebastine is a BCS2 compound, the ebastine can reach a peak in vivo quickly, the peak time is about 2 hours, and the peak time of a main metabolite carristine of the ebastine in vivo is 4.5-6 hours.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The invention discloses a method for detecting the content of p-hydroxybenzoic acid in an ebastine oral solution. The method comprises the following steps: step 1, setting chromatographic conditions; 2, preparing a solution; step 3, determination; step 4, limiting; the method is simple, convenient, rapid, high in accuracy and good in specificity, can measure the content of p-hydroxybenzoic acid in the ebastine oral solution, and is suitable for quality research and control of the ebastine oral solution.

1. The name of the design product: medicine packaging box (ibudilast oral solution). 2. The use of the design product: the design is used for the outer packaging of ibudilast oral solution. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: perspective view. 5. The design claimed contains color.

The invention discloses a continuous intelligent tabletting all-in-one machine for ebastine medicine, which comprises a cabinet, an operation table is arranged on the cabinet through a stand column, the operation table is provided with a machine shell, a rotatable disc table is correspondingly arranged on the machine shell, a rotating motor for driving the disc table to rotate is arranged at the lower end of the machine shell, and the lower end of the machine shell is provided with a rotating motor for driving the disc table to rotate. Stamping holes are evenly formed in the disc table at intervals, and the stamping holes are of a vertically-through through hole structure. The operation table serves as a bearing foundation of the whole equipment, a stable mounting platform is provided for core components such as the machine shell and the ejection assembly, the overall stability of the equipment during operation is guaranteed, when the rotating motor is started, the disc table is driven to rotate synchronously, the multiple punching holes are evenly formed in the disc table in the circumferential direction in a penetrating mode, and the punching efficiency is improved along with rotation of the disc table. The punching holes can be sequentially and circularly switched to a feeding station, a punching station, an ejection station and the like, continuity of the ebastine tablet pressing process is achieved, the production efficiency of the ebastine tablets is greatly improved, and the use requirement is met.

The application discloses an ebastine tablet, which comprises the following raw materials in parts by weight: 10 parts of ebastine, 30-36 parts of a disintegrating agent, 144-155 parts of a filling agent, 1-3 parts of a lubricant, 1-3 parts of an auxiliary solvent, 6-8 parts of a binder, wherein the disintegrating agent is a composite microsphere. The ebastine tablet can solve the technical problems of poor dissolution and low bioavailability.

The present invention discloses a carebastine salt and a use of the carebastine salt, relates to the field of pharmaceutical chemistry, and solves the problems of carebastine in the related art such as poor solid form, excessive impurities, instability, difficulty in purification, difficulty in scale-up synthesis, and unsuitability for medicinal use. The carebastine salt of the present invention includes, but is not limited to, acid addition salts or base addition salts, and particularly includes potassium salts, sodium salts, methanesulfonate and p-toluenesulfonate. The carebastine salt of the present invention has the use of preparing histamine H1 receptor antagonist drugs. The carebastine salt of the present invention has the characteristics such as easy purification, high stability, simple process and easy industrial production, and has good hygroscopicity characteristics and is convenient for storage. At the same time, the salt of the present invention can quickly enter the body to exert the efficacy, has good oral absorption, is superior to ebastine in safety and individual differences, and is a promising anti-allergic disease drug.

The invention provides an ebastine oral solution and a preparation method thereof, and belongs to the technical field of medicines. The ebastine oral solution comprises the following components in percentage by mass: 1-5% of ebastine, 5-10% of a composite dispersant, 5-10% of a sweetening agent, 0.5-1% of a defoaming agent and the balance of water, the composite dispersing agent is formed by mixing Tween 80, povidone and Arabic gum. According to the ebastine oral solution and the preparation method thereof, the composite dispersing agent is prepared from the Tween 80, the povidone and the Arabic gum, and the ebastine oral solution is prepared from the composite dispersing agent, so that the stability of the oral solution is remarkably improved, and the problem of layering after long-time storage is avoided.

The invention relates to the technical field of medicine synthesis, in particular to a synthesis and preparation method of an ebastine impurity. The preparation method comprises the following steps: step one, adding 20g of p-tert-butyl-4-chlorobutanone, adding 15g of sodium hydroxide and 100g of methylbenzene, stirring and heating until a reflux reaction is performed for 10-12 hours; 2, cooling the product obtained in the step 1 to below 50 DEG C, adding 60g of water, stirring for 15 minutes, standing to remove a water layer, adding a regulator to a toluene layer to regulate the pH value, and removing the water layer; step 3, washing the toluene layer with 50g of water, and removing a water layer; step 4, concentrating the methylbenzene layer under reduced pressure until no liquid drop exists to obtain 15.7 g of oily liquid, adding 20g of petroleum ether and 5g of ethyl acetate, stirring, cooling to 0-10 DEG C, and crystallizing for 1-2 hours; 5, the product in the step 4 is subjected to suction filtration, and a proper amount of detergent is added before suction filtration. The method has the advantages of being easy to operate, short in preparation period, high in yield, high in purity and the like.

Disclosed is a pharmaceutical composition comprising ebastine and alprazolam. Also disclosed is a method of using a pharmaceutical composition for treating a patient suffering from insomnia.

The present invention discloses a salt of carisoprodol and its uses, relating to the field of pharmaceutical chemistry, and solving the problems in the prior art such as poor solid form of carisoprodol, many impurities, instability, difficult purification, difficult scale-up synthesis, and inapplicability to medicine. The carisoprodol salt of the present invention includes but is not limited to acid salts or base salts, especially including potassium salt, sodium salt, methanesulfonate and p-toluenesulfonate. The salt of carisoprodol of the present invention has the use in preparing drugs for histamine H1 receptor antagonists. The carisoprodol salt of the present invention has the characteristics of easy purification, high stability, simple process and easy industrial production, and has good hygroscopicity characteristics, which is convenient for storage; at the same time, the salt of the present invention can quickly enter the body to exert a pharmacological effect, has good oral absorption, and its safety and individual differences are superior to ebastine, and it is a promising drug for treating allergic diseases.

The invention belongs to the technical field of medicines, and particularly relates to an ebastine orally disintegrating tablet and a preparation method thereof. According to the ebastine orally disintegrating tablet, the microcrystalline cellulose and the mannitol are used as filling agents at the same time, the average particle size of the microcrystalline cellulose and the mannitol is controlled, the problem that in the prior art, the ebastine orally disintegrating tablet is poor in dissolution performance is solved, and the ebastine orally disintegrating tablet has good disintegration performance. The ebastine orally disintegrating tablet disclosed by the invention is obtained by firstly granulating through a fluidized bed and then tabletting, the tabletting is smooth and not astringent in the pressing process and has better compressibility, the fluidized bed granulating process is simple and easy to operate and control, the equipment is easy to obtain, the production cost is lower, and the ebastine orally disintegrating tablet is suitable for large-scale production.